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Abstract
Retinal vascular diseases are a leading cause
of blindness in the Western world.
Advancement in the clinical management
of these diseases has been fast-paced, with
new treatments becoming available as well
as license extensions of existing treatments.
Vascular endothelial growth factor (VEGF)
has been implicated in certain retinal vascular
diseases, including wet age-related macular
degeneration (AMD), diabetic macular
oedema (DMO), and retinal vein occlusion
(RVO). Treatment of wet AMD and
visual impairment due to either DMO or
macular oedema secondary to RVO with an
anti-VEGF on an as needed basis, rather
than a ﬁxed schedule, allows an
individualised treatment approach;
providing treatment when patients are
most likely to beneﬁt from it, while
minimising the number of unnecessary
intravitreal injections. Thus, an individualised
treatment regimen reduces the chances of
over-treatment and under-treatment,
optimising both the risk/beneﬁt proﬁle of the
treatment and the efﬁcient use of NHS
resource. Streamlining of treatment for
patients with wet AMD and visual
impairment due to either DMO or macular
oedema secondary to RVO, by using one
treatment with similar posology across all
three diseases, may help to minimise burden
of clinic capacity and complexity and hence
optimise patient outcomes. Informed
treatment decisions and efﬁcient clinic
throughput are important for optimal patient
outcomes in the fast-changing ﬁeld of retinal
vascular diseases.
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Introduction
Some of the most frequently occurring ocular
diseases that cause certiﬁed visual loss are
associated with pathological retinal neovas-
cularisation and oedema. Of these diseases, wet
(neovascular) age-related macular degeneration
(AMD), diabetic retinopathy (proliferative
diabetic retinopathy (PDR) and diabetic
macular oedema (DMO)), and retinal
vein occlusion (RVO) are of particular
epidemiological importance as leading causes
of blindness. In the United Kingdom, AMD is
the leading cause of severe sight impairment
(legal blindness) and partial sight certiﬁcations
for all ages, accounting for over half of all visual
impairment certiﬁcations.
1 Diabetic retinopathy
is the third most common cause of blindness
and partial sight certiﬁcations for all age
groups in the United Kingdom (6.3 and 7.6%,
respectively);
1 however, in people of working
age (aged 16–64 years), diabetic retinopathy is
the leading cause of severe sight impairment
certiﬁcation (17.7%).
2 RVO is the second most
common type of retinal vascular disease (after
diabetic retinopathy) and includes branch RVO
(BRVO) and central RVO (CRVO), accounting
for o2% of all severe sight impairment and
partial sight certiﬁcations in the United
Kingdom.
1
Vascular endothelial growth factor A
(VEGF-A), a key regulator of angiogenesis and
vascular permeability (reviewed by Ferrara
et al
3) has been implicated in the pathogenesis of
retinal diseases associated with neovasculari-
sation and oedema, including wet AMD,
4,5
diabetic retinopathy (particularly, PDR and
DMO),
6,7 and RVO,
6,8,9 as well as other ocular
diseases such as retinopathy of prematurity.
6
Although angiogenesis is the result of a highly
complex molecular process involving several
different receptors and ligands, VEGF-A seems
to be a requirement for blood vessel growth in
both normal and pathological angiogenesis.
Please note that prescribing
information is available at
the end of this article as an
Appendix.
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developed for the treatment of these diseases.
Individualised treatment for retinal vascular diseases
In the years since the Human Genome Project
10 was
completed, huge progress has been made in unravelling
the genetic basis of disease and understanding what
drives diseases at a molecular level. By comparing
patterns and frequencies of single-nucleotide
polymorphisms (SNPs) in patients and controls, we have
become able to identify which SNPs are associated with
which diseases,
11 helping drive the concept and clinical
application of personalised medicine. Nowhere has this
been better exempliﬁed than in the ﬁeld of oncology,
where for example, only those patients who are most
likely to respond are given a targeted treatment based on
their genetic proﬁle (eg, HER2/ErbB2 in breast cancer).
Such is the potential for personalised medicine that the
UK government’s Technology Strategy Board has joined
forces with Cancer Research UK and other bodies to fund
the Stratiﬁed Medicines Programme,
12 which they see as
a signiﬁcant step in making targeted therapies available
for people with cancer in the United Kingdom. The
beneﬁt to patients of such an approach is clear.
Individualised treatment allows the identiﬁcation of
patients who are most likely to beneﬁt from the
treatment. Tailoring treatment to the individual patient in
this way should increase the chance of treatment success,
while sparing patients from unnecessary drug exposure
and risk of adverse events. Furthermore, avoiding
unnecessary treatment also has the potential to improve
the cost-effectiveness of treatment.
While treatment decisions for patients with retinal
vascular diseases are not currently based on genetics,
gene association work has already identiﬁed multiple
genes that may be associated with AMD,
13 and
understanding how these are implicated in the
pathogenesis of the disease opens up new research
strategies based on speciﬁc pathways and molecules. In
particular, dysregulation of the complement system has
been shown to have a major part in the pathogenesis of
wet and dry AMD,
14 and a number of AMD-associated
genetic loci have been identiﬁed.
13 Numerous companies
are currently developing genetically based and
complement-targeted therapies with the goal of reducing
complement-related AMD disease processes.
14,15
While in ophthalmology there is still some way to go
before individualised treatment approaches that are
based on genetics are available (as they are in certain
cancers), it is already possible to begin to consider a
similar patient-centred approach based on an
individual’s disease characteristics. It may be possible to
use vision loss, visual acuity (VA) instability, or other
signs of an active disease state as markers for requiring
treatment, rather than using ﬁxed dosing schedules. This
type of approach should reduce the risks associated with
over-treatment and under-treatment, thereby optimising
the risk/beneﬁt proﬁle of the treatment and the efﬁcient
use of NHS resource. There is evidence to support this
principle for the treatment of wet AMD, and visual
impairment due to either DMO or macular oedema
secondary to RVO with ranibizumab, as I will discuss
later in this article.
Current management and recent therapeutic
developments
Diagnosis
Wet AMD. Early diagnosis and treatment are vital for
vision preservation in retinal vascular diseases,
particularly wet AMD, because of the rapidly
progressive nature of the disease. Patients with wet AMD
typically present (to a general practitioner, optometrist,
or local eye unit/eye casualty)
16 with distortion, blurring,
or loss of vision with a rapid onset. Some patients with
unilateral wet AMD may be asymptomatic or report mild
vision distortion and only be detected in a routine
assessment.
17 The Royal College of Ophthalmologists
(RCOphth) recommends that suspected cases of wet
AMD should be referred directly to the nearest AMD
centre, eye casualty, or eye clinic, due to the aggressive
nature of the disease within 1 week of initial
presentation, with no more than 1 week between
evaluation and treatment.
DMO. DMO can arise as early as the mild non-
proliferative or as late as in the severe proliferative stages
of diabetic retinopathy.
18 DMO was deﬁned by the Early
Treatment of Diabetic Retinopathy Study (ETDRS) group
as being clinically signiﬁcant macular oedema when
there is retinal thickening and/or hard exudates within
500mm of the fovea or when there is a zone of oedema of
at least 1 disc diameter in width and part of which is
within 1 disc diameter from the fovea.
19 DMO appears as
retinal thickening on binocular stereoscopic slit-lamp
examination and can be conﬁrmed with retinal imaging
techniques such as optical coherence tomography
(OCT).
20 Macular oedema may also be present in wet
AMD and RVO, as well as other ocular diseases;
however, the natural history of DMO distinguishes it
from the other instances of macular oedema. In an
attempt to reduce diabetes-related visual impairment in
England, the English National Screening Programme for
Diabetic Retinopathy (ENSPDR) was set up and provides
annual photographic screening for every diabetic patient
(over the age of 12 years) in England. All patients
identiﬁed by screening as having sight-threatening
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21,22
RVO. Patients with RVO (including BRVO and CRVO)
typically present with painless loss of vision.
23,24 BRVO
(located in one of the branches of the central vein) is
more common than CRVO (located in the central vein
and affecting most of the retina) and usually occurs at
sites where arterioles cross over veins.
25,26 Retinal
imaging with ﬂuorescein angiography is crucial for
diagnosis and prognosis, allowing the identiﬁcation of
the speciﬁc type of RVO (eg, perfused vs non-perfused
and BRVO vs CRVO), the identiﬁcation of macular
oedema (if present), its extent, persistence, regression,
and degree of ischaemia.
27 OCT provides additional
information such as quantitative and qualitative
assessment of retinal thickness and the exact location of
the accumulated ﬂuid (within the retinal layer vs the
subretinal space).
27 Clinical features that may be
apparent at presentationFsuch as haemorrhage, cotton
wool spots, and macular oedema
27Foverlap with those
of other retinal vascular diseases, including diabetic
retinopathy, hypertensive retinopathy, and retinopathy
related to blood dyscrasias; thus, differential diagnosis is
important.
28
Management
Wet AMD. Treatment modalities for wet AMD have
improved dramatically over the past decade, prior to
which laser photocoagulation was the only available
treatment option.
29 Photodynamic therapy with
verteporﬁn was licensed for wet AMD with
predominantly classic subfoveal choroidal neovas-
cularisation (CNV) in 2000,
30 and recommended by the
National Institute for Health and Clinical Excellence
(NICE) in 2003 for patients with a conﬁrmed diagnosis of
classic subfoveal CNV with no sign of occult lesions.
31
However, it was only with the emergence of anti-VEGFs
that an effective treatment became available for patients
with wet AMD, regardless of lesion type. Licensed
anti-VEGFs for wet AMD include pegaptanib
(Macugen
s), which was authorised in the EU in 2006,
32
and ranibizumab (Lucentis
s!), authorised in 2007.
33
Ranibizumab is now considered the standard of care for
wet AMD. This is because, in addition to demonstrating
efﬁcacy in preventing visual loss in large, randomised,
controlled, clinical trials in the majority of patients,
34–37
ranibizumab has also been shown, on average, to provide
signiﬁcant gains in VA.
34–36
The approved posology of ranibizumab for wet AMD
consists of intravitreal injection (0.5mg) given monthly
and continued until maximum VA is achieved (deﬁned
as stable VA for 3 consecutive monthly assessments
while on treatment). Subsequently, patients are
monitored monthly for VA, and upon detection of
reduced VA due to wet AMD, treatment is resumed until
stable VA is reached.
38 Notably, the current approved
posology for ranibizumab represents an evolution in the
treatment dosing paradigm for wet AMD, towards an
individualised treatment approach, whereby injections
are only administered at times of VA instability, during
which patients are most likely to beneﬁt; hence,
minimising the chances of both under-treating or
over-treating.
The initial marketing authorisation for ranibizumab
was based on the pivotal trials MARINA
36 and
ANCHOR,
34 which investigated a monthly dosing
regimen, and a study which investigated a quarterly
regimen, PIER.
37 Almost all of the patients receiving
monthly 0.5-mg ranibizumab injections in MARINA and
ANCHOR maintained their VA at 1 year (94.6 and 96.4%,
vs 62.2 and 64.3% of controls, respectively; Po0.001 for
both), at least a third of patients (33.8% MARINA, 40.3%
ANCHOR) gained 15 or more letters of VA (vs 5.0 and
5.6% of controls, respectively; Po0.001 for both
comparisons) and, on average in both trials, there was an
improvement in VA (þ7.2 letters and þ11.3 letters in
MARINA and ANCHOR, respectively; Figure 1).
34,37
These outcomes were also maintained to 24 months.
35,36
However, in the PIER study, on average, patients who
received ﬁxed quarterly injections of 0.5mg ranibizumab
after a loading phase of 3 monthly injections, did not
maintain the initial gain in VA seen at 3 months (mean of
þ4.3 letters vs baseline) at the 12-month time point
(mean change from baseline  0.2 letters), although the
difference compared with sham remained statistically
signiﬁcant at year 1 (Figure 2).
37 Although, on average,
quarterly injections were not frequent enough to
maintain the initial gains in VA, an exploratory analysis
of the ranibizumab group in the PIER study showed that
patients could be stratiﬁed depending on their initial
increase in VA and whether they were able to maintain
this initial gain. Of the 40 patients (66%) who showed an
initial increase in VA, 16 patients (40%) were ‘sustained
responders’ (ie, had initial VA gains during the 3
monthly ranibizumab loading phase injections that were
sustained to 1 year with subsequent quarterly injections),
whereas the remainder of the patients showed a gradual
decline in VA from month 4 (with or without initial VA
gain), and may have beneﬁtted if treated more frequently
(Figure 3).
39 This subanalysis showed that different
patients needed different frequency of treatment to
maintain initial gain.
39 Therefore, the originally approved
posology for ranibizumab included a loading phase of 3
monthly doses followed by an individualised pro re nata
(PRN) maintenance phase with a VA-based retreatment
criteria (treatment was resumed upon a VA loss of 45
letters), because on average, VA appeared to plateau after
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40
Since these initial trials, further evidence has emerged
which suggested that an individualised patient-centred
approach would be more suitable. In a retrospective
analysis of data from studies evaluating monthly
ranibizumab injections including the MARINA and
ANCHOR trials as well as from the ranibizumab
monotherapy arm in the DENALI study (a Phase IIIb
study conducted in the United States and Canada),
41 the
time course of vision stability was evaluated.
42 This
retrospective analysis demonstrated that o20% of wet
AMD patients reached VA stability by month 3; however,
nearly 80% of patients reached stability within the ﬁrst
year of ranibizumab treatment. Furthermore, the analysis
showed that once VA stability is achieved, the
incremental VA beneﬁt of continued monthly injections
was minimal (the mean absolute change between the
visit in which visual stability was achieved and the
subsequent visit was p0.3 letters in the MARINA,
ANCHOR, and DENALI studies).
42 The impact of
treatment interruptions in ranibizumab monotherapy
arms in trials that used PRN or quarterly dosing
regimens including EXCITE,
43 SUSTAIN,
44 and MONT
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Figure 2 Mean changes from baseline in VA in patients with wet AMD with quarterly 0.5mg ranibizumab following a loading phase
of 3 monthly injections, in the PIER study. Only data from the licensed dose of ranibizumab (0.5mg) are shown. Arrows indicate
injection time point. P-value shown is for difference in mean change VA vs sham at 12 months. ETDRS, Early Treatment Diabetic
Retinopathy Study. Adapted from Regillo et al,
37 Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular
age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239–248, with permission from Elsevier & 2008.
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Figure 1 Mean changes from baseline in VA with monthly 0.5mg ranibizumab in patients with wet AMD with minimally classic/
occult CNV, in the MARINA study. Only data from the licensed dose of ranibizumab (0.5mg) are shown. P-value shown is for
difference in mean change in VA vs sham at 24 months. ETDRS, Early Treatment Diabetic Retinopathy Study. Adapted from Rosenfeld
et al.
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45 The analysis demonstrated
that once VA stability is achieved, the majority (60–80%)
of patients have stable VA 2 months after last injection.
42
Furthermore, the analysis demonstrated a consistent
trend for better VA outcomes when treatment is resumed
when VA is unstable (mean change after treatment
re-initiation following a visit in which unstable VA was
identiﬁed was þ2.7, þ4.3, and þ3.0 letters in the
EXCITE, SUSTAIN, and MONT BLANC studies,
respectively).
42
On the basis of these data, a revised ranibizumab wet
AMD posology was approved by the EMA in September
2011.
40 Ranibizumab can now be administered using a
three-step individualised PRN treatment regimen:
(1) treatment is initiated by monthly injections until
maximum VA is achieved (deﬁned as stable VA for
3 consecutive assessments while on ranibizumab);
(2) treatment is then interrupted and patients are
monitored monthly; (3) treatment is resumed if
monitoring indicates loss of VA associated with active
wet AMD and is continued monthly until VA is stable.
This approach allows patients the opportunity to receive
enough injections to gain maximum VA (at treatment
initiation), prevents unnecessary injections (by treatment
interruption once maximum VA has been achieved), and
allows patients to receive injections when they are most
likely to beneﬁt from them (at treatment re-initiation).
With the original posology, there was no opportunity for
further injections unless 45 letter VA loss was observed.
Waiting for a 45 letter VA drop may allow vision to be
lost that cannot be regained.
Bevacizumab, which is unlicensed for any ocular use,
is also sometimes used for treating wet AMD in clinical
practice. Bevacizumab is a humanised full-length
anti-VEGF monoclonal antibody that differs from
ranibizumab in a number of its properties, including
molecular structure, size and design, systemic
pharmacokinetics, and formulation. It is licensed only for
intravenous administration for the treatment of colorectal
cancer and certain cases of breast, renal, lung, ovarian,
fallopian tube, and peritoneal cancer.
46 Some differences
between the ocular and systemic safety proﬁles of
bevacizumab and ranibizumab have been suggested, but
despite the widespread use of bevacizumab for wet
AMD in clinical practice, evidence from large-scale
randomised trials were lacking until recently.
The head-to-head study of ranibizumab and
bevacizumab, CATT, is a 2-year, randomised, prospective
single-blind, non-inferiority trial to evaluate the
comparative safety and efﬁcacy of the two agents.
In the 1-year primary end point analysis, while the
non-inferiority limit was met for monthly bevacizumab
compared with monthly ranibizumab, the non-inferiority
limit (5 letters difference) was not met for PRN
bevacizumab (n¼300) compared with either monthly
bevacizumab (n¼286) or monthly ranibizumab (n¼298).
From an anatomical perspective, 4 weeks after their ﬁrst
injection, no ﬂuid was seen on the OCT in 17.3% of
bevacizumab-treated patients, while 27.5% of
ranibizumab-treated patients were dry on OCT
(Po0.001).
47 The mean number of injections required in
the bevacizumab PRN arm was signiﬁcantly higher than
the number of PRN ranibizumab injections required
(7.7±3.5 and 6.9±3.0, respectively; Po0.003).
47
Consistent with the move towards individualised
treatment with ranibizumab, PRN ranibizumab was non-
inferior to monthly ranibizumab dosing.
47 Importantly,
the observed mean VA gain from baseline to 1 year in the
ranibizumab PRN arm of the CATT study (6.8 letters)
47
represents the best outcome in randomised controlled
trials for 1-year VA gain, with less than monthly
ranibizumab dosing in comparison with the relevant
arms of PIER (mean gain of 4.3 letters in the 0.5-mg
quarterly group),
37 EXCITE (mean gain of 3.8 letters in
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Figure 3 Mean changes from baseline in VA in wet AMD in three subgroups of patients receiving 0.5mg ranibizumab in the PIER
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43 SUSTAIN (mean gain of
3.6 letters using a VA/OCT-based PRN regimen),
44 and
SAILOR (a phase IIIb study in which cohort 1 evaluated
0.3 and 0.5mg ranibizumab using VA/OCT-based PRN
regimen; mean gain of 2.3 letters in the 0.5-mg group).
48
Thus, the ﬁndings of the CATT study supports the
currently approved posology for ranibizumab, by
suggesting that a more reﬁned individualised regimen
may optimise clinical outcomes while reducing the
number of injections.
While not powered to identify rare but serious adverse
events, safety differences were also identiﬁed in the
CATT study, despite the population of the study being
relatively ﬁt due to patients being excluded from
entering the study if they had signiﬁcant concomitant
medical conditions. No signiﬁcant differences were
observed between ranibizumab and bevacizumab in
rates of death (1.3 and 1.4% for the ranibizumab and
bevacizumab monthly groups, respectively; 1.7 and 3.7%
for the respective PRN groups; P¼0.18 for comparing all
groups, P¼0.22 for between drug comparison), nonfatal
myocardial infarction (0.7% for both the ranibizumab
and bevacizumab monthly groups; 1.0 and 0.3% for the
respective PRN groups; P¼0.78 for comparing all
groups, P¼0.73 for between drug comparison), or
nonfatal stroke (1.0 and 0.7% for the ranibizumab and
bevacizumab monthly groups, respectively; 0.3 and 0.7%
for the respective PRN groups; P¼0.88 for comparing all
groups, P¼1.0 for between drug comparison).
47
However, comparing rates of serious systemic adverse
events associated with hospitalisation between
ranibizumab- and bevacizumab-treated patients
(combining dosing-regimen groups) demonstrated a
statistically signiﬁcant higher rate with bevacizumab
(24.1 (141) vs 19.0% (114); RR 1.29; 95% CI 1.01–1.66;
P¼0.04).
47 Intravitreal bevacizumab also led to a
signiﬁcantly higher incidence of gastrointestinal
disorders (including haemorrhage) compared with
ranibizumab (2.6 vs 0.8%; P¼0.02). These observed
adverse events are consistent with those noted in the
Summary of Product Characteristics for bevacizumab
and are known to be potential risks related to systemic
exposure of anti-VEGFs.
46
DMO. The standard of care in DMO consisted of
focal/grid laser photocoagulation (laser treatment) since
the trial of the ETDRS in 1985, which demonstrated that
this treatment substantially reduced the risk of visual
loss.
49 Some recent trials showed that laser treatment
may also improve vision. For example, the Diabetic
Retinopathy Clinical Research Network (DRCR.net)
randomised study compared focal/grid
photocoagulation to intravitreal administration of the
corticosteroid triamcinolone acetonide (IVTA). The study
showed that from baseline to year 3, laser treatment was
associated with a mean gain of 5 letters and with an
improved VA by X10 letters in 44% of patients
(vs worsening VA by X10 letters in 12% of patients).
50
Pharmacotherapeutic options in DMO were very
limited until recently. Unlicensed and contraindicated
use of IVTA is widespread and its rationale is based on
the anti-angiogenic properties of corticosteroids (possibly
due to downregulation of VEGF).
51,52 Notably, in the
IVTA vs laser DRCR.net study, at 4 months, VA in the
4-mg IVTA group was superior to that in the 1-mg IVTA
group (mean difference between the groups adjusted
for baseline VA and prior macular photocoagulation,
3.6 letters; P¼0.001) and in the laser-treated group (mean
difference between the groups adjusted for baseline VA
and prior macular photocoagulation, 3.8 letters;
Po0.001); however, the VA differences between the
groups disappeared by the end of year 1. By year 3, laser
treatment conferred better VA outcomes compared with
IVTA treatment (mean difference between laser and 1-mg
IVTA groups adjusted for baseline VA and prior macular
photocoagulation, 5.6 letters; 95% CI, 0.8–10.4; respective
difference between laser and 4-mg IVTA groups, 4.7
letters; 95% CI, 0.0–9.5).
50,53 Furthermore, IVTA may
increase the risk for secondary glaucoma and secondary
cataracts.
50
Ranibizumab was authorised in the EU for the
treatment of visual impairment due to DMO in 2011,
40
thereby signiﬁcantly expanding the treatment
armamentarium for DMO. Phase II studies such as
READ-2 and RESOLVE demonstrated efﬁcacy and
tolerability of ranibizumab in DMO.
54,55 Phase III studies
of ranibizumab in DMO further supported its utility in
this indication. The independent DRCR.net Protocol I
study was a 4-arm trial (854 eyes) evaluating
ranibizumab plus prompt laser to ranibizumab plus
deferred laser (X24 weeks), IVTA plus prompt laser, and
sham injection plus prompt laser.
56 Ranibizumab (or
sham) injections were administered monthly for the ﬁrst
3 months (totalling four injections) followed by PRN
dosing based on VA/OCTcriteria.
56 The Protocol I study
showed that at 1 year, ranibizumab plus prompt or
deferred laser was superior to sham plus laser (mean
increase of 9 letters for both ranibizumab groups vs 3
letters for the sham plus laser group; Po0.001 for
comparisons vs sham), whereas IVTA plus laser was
comparable to sham plus laser (mean increase of 4 letters
for the IVTA plus laser group; P¼0.31 vs sham plus
laser).
56 Two-year VA outcomes were similar to 1-year
outcomes (Figure 4).
56 The RESTORE phase III study
(N¼345) compared ranibizumab monotherapy
(plus sham laser) to ranibizumab plus laser to laser alone
(plus sham injections).
57 Ranibizumab (0.5mg) regimen
included a loading phase of 3 monthly injections
followed by PRN dosing (based on VA stability
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57 The mean number of ranibizumab injections in
the ranibizumab and ranibizumab/laser groups was
7.0±2.8 and 6.8±3.0, respectively.
57 The mean average
change in best corrected visual acuity (BCVA) letter score
from baseline to month 1 through month 12 was
signiﬁcantly superior with ranibizumab and
ranibizumab plus laser vs laser alone (6.1, 5.9, and 0.8
letters, respectively; Po0.0001 for both comparisons vs
laser alone); the difference between the two ranibizumab
groups was not signiﬁcant (P¼0.61).
57 The safety proﬁle
of ranibizumab in DMO trials was consistent with that of
ranibizumab in wet AMD.
56,57 In addition to the
DRCR.net and RESTORE studies, data from two other
Phase III studies (RISE, RIDE) have strengthened the
evidence for ranibizumab in DMO.
58,59
RVO. The standard of care for macular oedema
secondary to BRVO consisted of grid laser
photocoagulation since the Branch Vein Occlusion Study
demonstrated the efﬁcacy of this treatment approach (over
no treatment).
60 In contrast, as the Central Vein Occlusion
Study showed no VA beneﬁt for grid laser photocoa-
gulation (over no treatment) in patients with macular
oedema secondary to CRVO at any follow-up point,
61 the
standard of care for CRVO was observation until the recent
development of pharmacotherapeutic options.
The rationale for using corticosteroids for macular
oedema secondary to RVO is based on their anti-
angiogenic and anti-inﬂammatory properties.
51,52,62 The
SCORE-BRVO studyFa randomised trial (N¼411)
comparing IVTA (1 and 4mg) to standard-of-care (grid
laser photocoagulation that may be prompt or deferred
depending on the absence/presence of dense macular
haemorrhage) in patients with macular oedema
secondary to BRVOFfailed to demonstrate an advantage
for IVTA over prompt/deferred laser.
63 In this study, the
mean letter gain from baseline to 1 year was not
statistically different across the treatment groups (4.2, 5.7,
and 4.0 letters for the standard care, 1-mg IVTA, and
4-mg IVTA groups, respectively; P¼0.70), and neither
was the difference in the proportion of patients who
gained X15 letters from baseline to 1 year (28.9, 25.6, and
27.2% for the standard care, 1-mg IVTA, and 4-mg IVTA
groups, respectively; P¼0.89 for all comparisons).
63
Rates of elevated intraocular pressure (IOP) and cataracts
were comparable in the standard-of-care and 1-mg IVTA
groups and higher in the 4-mg IVTA group. There was,
however, a dose-dependent higher frequency initiation of
IOP-lowering medications and an increase in lens
capacity onset/progression in the IVTA groups
compared with the standard care group.
63 In contrast
to the SCORE-BRVO study, the complementary
SCORE-CRVO trialFa randomised trial (N¼271)
comparing IVTA (1 and 4mg) to observation in patients
with macular oedema secondary to CRVOFdemonstrated
a superiority for IVTA over observations in these
patients.
64 In SCORE-CRVO study, from baseline to
1 year, IVTA-treated patients lost, on average, fewer
letters compared with the observation group (loss of 12.1,
1.2, and 1.2 letters for the observation, 1-mg IVTA, and
4-mg IVTA groups, respectively; P¼0.004); similarly, a
higher proportion of patients in the IVTA groups gained
X15 letters from baseline to 1 year (6.8, 26.5, and 25.6%
for the observation, 1-mg IVTA, and 4-mg IVTA groups,
respectively; P¼0.001 for both comparisons vs
observation).
64 Similar to the SCORE-CRVO ﬁndings,
rates of IOP and cataracts were comparable in the
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4-mg IVTA group, and there was a dose-dependent higher
frequency initiation of IOP-lowering medications in the
IVTA groups compared with the observation group.
64
Another corticosteroid that has been investigated and
is now authorised for the treatment of RVO is
dexamethasone intravitreal implant (DEX implant;
Ozurdex
s). The GENEVA studies (N¼1267) were
randomised trials comparing DEX implant (0.35 or
0.7mg) with sham treatment in patients with macular
oedema secondary to BRVO or CRVO at 6 months,
followed by an open-label 6-month extension phase in
which patients could receive a second DEX implant
(0.7mg) based on BCVA and retinal thickness.
65,66 The
studies demonstrated that from baseline to 6 months,
mean VA improvement was better in the DEX groups
than in the sham group (Pp0.006); the greatest between-
group difference was at day 60 (B7 letters).
65 From day
30 to 90 (but not later), the proportion of patients with
X15 letter gain was signiﬁcantly greater in the DEX
groups (Po0.001); at day 60, 29% of patients in both DEX
groups gained X15 letters compared with 11% of the
sham group (Po0.001),
65 and this was maintained at 12
months in patients who received two 0.7-mg DEX
implants (30 and 32%, 60 days after the ﬁrst and second
implant, respectively).
66 Furthermore, patients in the
DEX groups achieved the 15-letter gain faster than those
in the sham group (Po0.001 vs sham).
65 Rates of elevated
IOP were overall higher in the DEX groups than the
sham group (Pp0.002) and the percentage of eyes
receiving IOP-lowering medication increased in the DEX
implant treatment groups from B6% at the beginning of
the study to B24% by day 180, whereas there was no
change in the sham group. By day 180, there was no
difference in the rates of elevated IOP between the DEX
groups and sham.
65 Rates of cataracts were not
signiﬁcantly different between the DEX (7.3% in 0.7-mg
group, 4.1% in 0.35-mg group) and sham (4.5%) groups
at 6 months.
65 However, at 12 months, patients who
received two 0.7-mg DEX implants had a higher rate of
cataract progression compared with sham (29.8% of
phakic eyes vs 5.7% of phakic eyes, respectively).
66
Ranibizumab was authorised in the EU for the
treatment of visual impairment due to macular oedema
secondary to RVO in 2011,
40 thereby expanding the
treatment options for RVO using an anti-VEGF approach.
Pilot studies of ranibizumab in RVO provided
preliminary proof for the potential utility of ranibizumab
in this disease
67–69 and provided the rationale for the two
Phase III 12-month studies, BRAVO (in patients with
macular oedema secondary to BRVO; N¼397)
25,70 and
CRUISE (in patients with macular oedema secondary to
CRVO; N¼392).
71,72 In both studies participants were
randomised to receive monthly intravitreal ranibizumab
(0.3 or 0.5mg) or sham injections from day 0 to month 5
(thereafter, all patients with study eye BCVA of p20/40
or central retinal thickness of X250mm received
ranibizumab PRN).
25,70–72 In the BRAVO study, patients
could receive rescue laser treatment once during the
treatment period and once during the observation period
if criteria were met.
70 In both studies, the mean letter gain
from baseline to month 6 was superior with ranibizumab
compared with sham group. In BRAVO, patients gained
18.3 and 7.3 letters in the 0.5-mg group and sham group,
respectively (Po0.0001 for ranibizumab vs sham),
25 and
in CRUISE, the respective values were 14.9 and 0.8 letters
(Po0.0001 for ranibizumab vs sham).
72 The treatment
beneﬁts were maintained through month 12 on a PRN
regimen (Figure 5). Also, in both studies, the proportion
of patients with X15 letter gain from baseline was
signiﬁcantly higher in the ranibizumab groups (vs sham)
at 6 months (BRAVO: 61.1 and 28.8% of patients in the
0.5mg and sham groups; Po0.0001 for ranibizumab vs
sham;
25 CRUISE: 47.7 and 16.9% for the respective
groups; Po0.0001).
72 These proportions were maintained
in both studies from month 6 through 12 when
ranibizumab was given PRN. A total number of
2.7 (BRAVO) and 3.3 (CRUISE) 0.5-mg ranibizumab
injections were needed to maintain patients visual
stability from months 6 to 12.
70,71 Safety proﬁle of
ranibizumab in these trials was consistent with that
found in other studies.
70,71
The viability of a stability-based individualised
approach for ranibizumab in RVO was evaluated in a
retrospective analysis conducted using data from the
ranibizumab arms (pooled doses) in the Phase III BRAVO
and CRUISE trials (in which patients received monthly
injections from day 0 to month 5 and were dosed PRN
thereafter (months 6–11)). The analysis demonstrated
that 59 and 53% of ranibizumab-treated patients in the
BRAVO and CRUISE trials, respectively, reached VA
stability (p3 letters in 3 consecutive monthly visits with
treatment at the ﬁrst two visits) up to month 6.
73 The
mean VA change 1 month after ranibizumab treatment at
a VA stability visit was small (BRAVO, 0.8 letters;
CRUISE, 1.5 letters). During the PRN period, 1 month
after ranibizumab re-initiation, mean VA gains were
clinically relevant (BRAVO, 7.1 letters; CRUISE, 9.3
letters).
73 Thus, this retrospective analysis is consistent
with that conducted for the wet AMD trials and supports
the currently approved posology.
Notably, the approved posology for all the
ranibizumab indications is similar (the exception is that
for visual impairment due to DMO or macula oedema
secondary to RVO, further treatment is not
recommended if there is no response after the ﬁrst three
injections; this is not the case for wet AMD).
38 This
harmonisation facilitates patient ﬂow as it allows all
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secondary to RVO to be treated using the same approach.
The impact of anti-VEGF treatments for DMO and
RVO on clinic capacity
Following the introduction of anti-VEGF treatment for
wet AMD, there was a consequent rise in the number
of wet AMD patients, potentially suitable for treatment
as well as the number (frequency) of follow-up
appointments. The associated increase in clinical
workload has been substantial and there is concern that
the introduction of anti-VEGF treatments for DMO and
RVO could further exacerbate pressure on clinic capacity
in the hospital eye service.
The prevalence of diabetes (particularly type II) is
increasing in the Western world with the ageing
population. In the United Kingdom (in 2009), it was
estimated that 2.6 million people were diagnosed with
diabetes and that B500000 more people had
undiagnosed diabetes; the prevalence of diabetes in the
adult population ranged from 3.9 (Scotland) to 5.1%
(England).
74 In an epidemiologic study of patients with
type I diabetes (in the United States), the 14-year rates of
progression to proliferative retinopathy and incidence of
macular oedema were 37 and 26%, respectively.
75 In a
cohort study evaluating patients with type II diabetes in
the United Kingdom, the cumulative 5-year incidence of
developing sight-threatening diabetic retinopathy in
patients without retinopathy at baseline was 3.9%.
76 In
contrast to diabetes and its associated retinal morbidities,
RVO is relatively infrequent. In an epidemiologic study
in the United States, the prevalence of BRVO was 0.6%
and the prevalence of CRVO was 0.1%.
77 In a recent
analysis of pooled data from population studies
worldwide, the overall RVO prevalence was 0.52%
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individuals worldwide affected by RVO.
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The authorisation of anti-VEGF therapy for DMO and
macular oedema secondary to RVO represented an increase
in the number of patients eligible for anti-VEGF therapy, an
important factor with respect to clinic capacity pressures.
The RCOphth issued a preferred practice guidelines
addressing the diabetic retinopathy screening and
ophthalmology clinic set up in England as well as a
guidance for management of RVO addressing patient
pathways.
20,21 Ideally, referrals of patients with diabetic
retinopathy should come through ENSPDR; whereas
referrals of patients with RVO are likely to come from an
optometrist, general practitioner, or other health
workers.
20,21 In both cases, referral pathways should be
streamlined to ensure timely treatments. Intravitreal
injection facilities may be integrated into the patient
pathways (similar to the way laser clinics are integrated in
the guidance for diabetic retinopathy patients), so that
patients could beneﬁt from effective monitoring and care.
21
Intravitreal injection facilities may be shared with wet
AMD services. Importantly, the uniﬁed ranibizumab
posology for wet AMD, DMO, and macular oedema
secondary to RVO should streamline treatment of all
these indications, thereby maximising clinic capacity.
Conversely, utilising different treatments for each of
these diseases may impact negatively on the capacity
burden in specialist retinal clinics.
Summary
Treatment for retinal vascular diseases including wet
AMD, DMO, and RVO has improved dramatically in
recent years, due primarily, to the development and
authorisation of anti-VEGF therapy. Treatment regimens
have evolved through experience gained in clinical trials
and clinical practice. The current treatment regimen for
ranibizumab across these indications reﬂects an
individualised treatment approach designed to treat
patients when they could beneﬁt the most while
minimising the number of unnecessary intravitreal
injections, and hence the risk of adverse events. To
maximise patient outcomes, care should be taken to
integrate intravitreal injection facilities into the patient
pathways for DMO and RVO (similar to the approach
taken for wet AMD); the new uniﬁed posology for
ranibizumab may streamline the treatment of these
patients, thereby minimising impact on clinic capacity
and optimising patient outcomes.
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Lucentis
s! (ranibizumab), ABBREVIATED UK
PRESCRIBING INFORMATION
Please refer to the SmPC before prescribing Lucentis
10mg/ml solution for injection.
Presentation: A glass single-use vial containing 0.23ml
solution containing 2.3mg of ranibizumab (10mg/ml).
Indications: The treatment in adults of neovascular
(wet) age-related macular degeneration (AMD), the
treatment of visual impairment due to diabetic macular
oedema (DMO), or the treatment of visual impairment
due to macular oedema secondary to retinal vein
occlusion (branch RVO or central RVO).
Administration and dosage: Single-use vial for
intravitreal use only. Lucentis must be administered by a
qualiﬁed ophthalmologist experienced in intravitreal
injections under aseptic conditions. The recommended
dose is 0.5mg (0.05ml).
For treatment of wet AMD: Treatment is given
monthly and continued until maximum visual acuity is
achieved, i.e., the patient’s visual acuity is stable for three
consecutive monthly assessments performed while on
ranibizumab. Thereafter, patients should be monitored
monthly for visual acuity. Treatment is resumed when
monitoring indicates loss of visual acuity due to wet
AMD. Monthly injections should then be administered
until stable visual acuity is reached again for three
consecutive monthly assessments (implying a minimum
of two injections). The interval between two doses should
not be shorter than 1 month.
For treatment of visual impairment due to either
DMO or macular oedema secondary to RVO: Treatment
is given monthly and continued until maximum visual
acuity is achieved, i.e., the patient’s visual acuity is stable
for three consecutive monthly assessments performed
while on ranibizumab treatment. If there is no
improvement in visual acuity over the course of the ﬁrst
three injections, continued treatment is not recommended.
Thereafter, patients should be monitored monthly for
visual acuity. Treatment is resumed when monitoring
i n d i c a t e sl o s so fv i s u a la c u i t yd u et oD M Oo rt om a c u l a r
oedema secondary to RVO. Monthly injections should then
be administered until stable visual acuity is reached again
for three consecutive monthly assessments (implying a
minimum of two injections). The interval between two
doses should not be shorter than 1 month.
Lucentis and laser photocoagulation in DMO and in
macular oedema secondary to BRVO: When given on
the same day, Lucentis should be administered at least
30minutes after laser photocoagulation. Lucentis can be
administered in patients who have received previous
laser photocoagulation. Before treatment, evaluate the
patient’s medical history for hypersensitivity. The patient
should also be instructed to self-administer anti-
microbial drops, 4 times daily for 3 days before and
following each injection.
Children and adolescents: Not recommended for use
in children and adolescents due to a lack of data.
Elderly: No dose adjustment is required in the elderly.
There is limited experience in patients older than
75 years with DMO.
Hepatic and renal impairment: Dose adjustment is not
needed in these populations.
Contraindications: Hypersensitivity to the active
substance or excipients. Patients with active or suspected
ocular or periocular infections. Patients with active
severe intraocular inﬂammation.
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for intravitreal injection only. Intravitreal injections have
been associated with endophthalmitis, intraocular
inﬂammation, rhegmatogenous retinal detachment,
retinal tear, and iatrogenic traumatic cataract. Monitor
during week following injection for infections. Patients
should be instructed to report symptoms suggestive of
any of the above without delay. Transient increases in
intraocular pressure (IOP) within 1hour of injection and
sustained IOP increases have been identiﬁed. Both IOP
and perfusion of the optic nerve head should be
monitored and managed appropriately. Concurrent use
in both eyes has not been studied and could lead to an
increased systemic exposure. There is a potential for
immunogenicity with Lucentis, which may be greater in
subjects with DMO. Patients should report an increase in
severity of intraocular inﬂammation. Lucentis should not
be administered concurrently with other anti-VEGF
agents (systemic or ocular). Withhold dose and do not
resume treatment earlier than the next scheduled
treatment in the event of the following: a decrease in best
corrected visual acuity of (BCVA) X30 letters compared
with the last assessment of visual acuity; an intraocular
pressure of X30mmHg; a retinal break; a subretinal
haemorrhage involving the centre of the fovea, or if the
size of the haemorrhage is X50% of the total lesion area;
performed or planned intraocular surgery within the
previous or next 28 days. Risk factors associated with the
development of a retinal pigment epithelial (RPE) tear
after anti-VEGF therapy for wet AMD include a large
and/or high pigment epithelial retinal detachment.
When initiating Lucentis therapy, caution should be
taken in patients with these risk factors for RPE tears.
Discontinue treatment in cases of rhegmatogenous
retinal detachment or stage 3 or 4 macular holes. There is
only limited experience in the treatment of subjects with
DMO due to type I diabetes. Lucentis has not been
studied in patients who have previously received
intravitreal injections, in patients with active systemic
infections, proliferative diabetic retinopathy, or in
patients with concurrent eye conditions such as retinal
detachment or macular hole. There is also no experience
of treatment with Lucentis in diabetic patients with an
HbA1c over 12% and uncontrolled hypertension. There
are limited data on safety in the treatment of DMO and
macular oedema due to RVO patients with prior history
of stroke or transient ischaemic attacks. Since there is a
potential risk of arterial thromboembolic events
following intravitreal use of VEGF (vascular endothelial
growth factor) inhibitors, caution should be exercised
when treating such patients. There is limited experience
with treatment of patients with prior episodes of RVO
and of patients with ischaemic BRVO and CRVO.
Treatment is not recommended in RVO patients
presenting with clinical signs of irreversible ischaemic
visual function loss.
Interactions: No formal interaction studies have been
performed. In wet AMD adjunctive use of verteporﬁn
photodynamic therapy (PDT) and Lucentis in an open
study showed an incidence of intraocular inﬂammation
following initial combination treatment of 6.3% (2 of 32
patients). In DMO and BRVO adjunctive use of laser
therapy and Lucentis was not associated with any new
ocular or non-ocular safety ﬁndings.
Pregnancy and lactation: Women of childbearing
potential should use effective contraception during
treatment. No clinical data on exposed pregnancies are
available. Ranibizumab should not be used during
pregnancy unless the expected beneﬁt outweighs the
potential risk to the foetus. For women who wish
to become pregnant and have been treated with
ranibizumab, it is recommended to wait at least 3 months
after the last dose of ranibizumab before conceiving.
Breast-feeding is not recommended during the use of
Lucentis.
Driving and using machines: The treatment
procedure may induce temporary visual disturbances,
and patients who experience these signs must not
drive or use machines until these disturbances
subside.
Undesirable effects: wet AMD population: Serious
adverse events related to the injection procedure
included endophthalmitis, rhegmatogenous retinal
detachment, retinal tear, and iatrogenic traumatic
cataract. Other serious ocular events among Lucentis-
treated patients included intraocular inﬂammation and
increased intraocular pressure. The safety data below
includes all adverse events suspected to be due to the
injection procedure or medicinal product in the wet
AMD trial population.
Very common: Intraocular pressure increased,
headache, vitritis, vitreous detachment, retinal
haemorrhage, visual disturbance, eye pain, vitreous
ﬂoaters, conjunctival haemorrhage, eye irritation, foreign
body sensation in eyes, lacrimation increased,
blepharitis, dry eye, ocular hyperaemia, eye pruritus,
arthralgia, nasopharyngitis.
Common: Anaemia, retinal degeneration, retinal
disorder, retinal detachment, retinal tear, detachment of
the retinal pigment epithelium, retinal pigment
epithelium tear, visual acuity reduced, vitreous
haemorrhage, vitreous disorder, uveitis, iritis,
iridocyclitis, cataract, cataract subcapsular, posterior
capsule opaciﬁcation, punctuate keratitis, corneal
abrasion, anterior chamber ﬂare, vision blurred, injection
site haemorrhage, eye haemorrhage, conjunctivitis,
conjunctivitis allergic, eye discharge, photopsia,
photophobia, ocular discomfort, eyelid oedema, eyelid
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reactions, hypersensitivity, and anxiety.
DMO and RVO populations: Ocular and non-ocular
events in the DMO and RVO trials were reported with a
frequency and severity similar to those seen in the wet
AMD trials with the addition of urinary tract infection,
which was found to be ‘common’ in the DMO
population.
Product-class-related adverse reactions: There is a
theoretical risk of arterial thromboembolic events
following intravitreal use of VEGF inhibitors. A low-
incidence rate of arterial thromboembolic events was
observed in the Lucentis clinical trials in patients with
AMD and DMO and RVO, and there were no major
differences between the groups treated with ranibizumab
compared to control. Please refer to the SmPC for full
listing of all undesirable effects.
For United Kingdom: Adverse events should be
reported. Reporting forms and information can be
found at www.yellowcard.mhra.gov.uk. Adverse events
should also be reported to Novartis Pharmaceuticals
UK Ltd on (01276) 698370.
Legal category: POM, UK Basic NHS cost: d742.17.
Marketing authorisation number: EU/1/06/374/001
Marketing authorisation holder: Novartis Europharm
Limited, Wimblehurst Road, Horsham, West Sussex
RH12 5AB, UK. Full prescribing information, including
SmPC, is available from: Novartis Pharmaceuticals,
Frimley Business Park, Frimley, Camberley, Surrey GU16
7SR, UK. Tel: 01276 692255; Fax: 01276 692508.
Date of PI preparation: September 2011.
VISUDYNE
s (verteporﬁn), ABBREVIATED UK
PRESCRIBING INFORMATION
Presentation: Glass vial containing 15mg of verteporﬁn
as powder. Indications: Treatment of age-related macular
degeneration (AMD) in adult patients with
predominantly classic subfoveal choroidal
neovascularisation or subfoveal choroidal
neovascularisation secondary to pathological myopia.
Dosage and administration: A 10-minute intravenous
infusion of Visudyne (30ml solution) at a dose of
6mg/m
2 body surface area. This is followed by the
activation of Visudyne 15minutes after the start of the
infusion using a diode laser generating non-thermal red
light (wavelength 689nm (±3nm). At the recommended
light intensity of 600mW/cm
2, it takes 83seconds to
deliver the required light dose of 50J/cm
2. Reevaluate
every 3 months; if recurrent CNV leakage occurs,
Visudyne therapy may be given up to 4 times per year.
Contraindications: Porphyria, known hypersensitivity
to verteporﬁn or to any of the excipients, or severe
hepatic impairment.
Precautions: Due to photosensitivity, avoid exposure of
unprotected skin, eyes, or other body organs to direct
sunlight or bright indoor light for 48hours after infusion.
UV sunscreens are not effective at protecting against
photosensitivity reactions. Exercise caution in moderate
hepatic impairment, biliary obstruction, and treatment under
general anaesthesia. If severe decrease of vision (equivalent to
4 lines or more) occurs within 1 week after treatment, do not
re-treat at least until vision completely recovers to
pretreatment level. If extravasation occurs, stop infusion
immediately. Protect the affected area thoroughly from bright
direct light until swelling and discolouration have
disappeared. Visudyne containss m a l la m o u n t so fb u t y l a t e d
hydroxytoluene that may be irritant to eyes, skin, and
mucous membranes, it should be washed off extensively
with water in the event of direct contact. Patients should be
under close medical supervision during Visudyne infusion.
Chest pain, vasovagal reactions (posture-related), and
hypersensitivity reactions have been reported.
Interactions: No speciﬁc drug–drug interaction studies
have been conducted in humans. Concomitant use of
other photosensitising agents (eg, tetracyclines,
sulphonamides, phenothiazines, sulphonylurea,
hypoglycaemic agents, thiazide diuretics, and
griseofulvin) could increase the potential for
photosensitivity reactions.
Pregnancy and lactation: Visudyne should be used in
pregnant women only if the beneﬁt justiﬁes the potential
risk to the foetus. Do not administer to nursing mothers
or stop breast-feeding for 48hours after administration.
Effects on ability to drive and use machines: Do not
drive or use machines as long as symptoms such as
abnormal vision persist.
Undesirable effects: Most adverse reactions were mild
to moderate, transient in nature, and similar in patients
with either pathological myopia or AMD.
Reported frequency of ocular adverse reactions:
Common (X1/100 to o1/10): Severe reduced visual
acuity, visual impairment such as reduced visual acuity,
blurred, fuzzy vision, or photopsia as well as visual ﬁeld
defect such as scotoma, grey or dark haloes, and black
spots. Uncommon (X1/1000 to o1/100): Retinal
detachment (non-rhegmatogenous), subretinal/retinal
haemorrhage, vitreous haemorrhage. Rare (X1/10000 to
o1/1000): Retinal or choroidal vessel non-perfusion.
Frequency not known: Retinal pigment epithelial tear.
Reported frequency of systemic adverse reactions:
Common (X1/100 to o1/10): Hypercholesteraemia,
nausea, photosensitivity reaction, injection site pain,
injection site oedema, injection site inﬂammation,
injection site extravasation, asthenia, infusion-related
reaction primarily presented as back pain. Uncommon
(X1/1000 to o1/100): Hyperaesthesia, hypertension,
injection site hypersensitivity, injection site haemorrhage,
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known: Hypersensitivity, vasovagal reactions,
myocardial infarction, injection site blister, infusion-
related chest pain.
Prescribers should consult the Summary of Product
Characteristics for full information about other
side effects.
Legal category: POM. Packaging quantities: Each vial
containing 15mg verteporﬁn. Price:U Kd850. Marketing
authorisation number: EU/1/00/140/001.
Marketing authorisation holder: Novartis Europharm
Limited, Wimblehurst Road, Horsham, West Sussex
RH12 5AB, UK.
Date of preparation: 14 May 2010. Visudyne is a
registered trade mark. Full prescribing information,
including SmPC, is available from Novartis
Pharmaceuticals, Frimley Business Park, Frimley,
Camberley, Surrey GU16 7SR, UK. Tel: 01276 692255.
Fax: 01276 692508.
Adverse events should be reported. Reporting forms
and information can be found at
www.yellowcard.mhra.gov.uk. Adverse events should
also be reported to Novartis Pharmaceuticals UK Ltd on
(01276) 698370.
Job code: LUC12-C005.
Date of preparation: January 2012.
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